SA
SANA.US Sana Biotechnology Inc
- Market cap
- USD 563M
- P/E
- -
- P/B
- 3.11x
- ROE
- -66.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SANA.US undervalued?
Graham numberThe Graham number of Sana Biotechnology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sana Biotechnology Inc fundamental analysis
No fundamental analysis for Sana Biotechnology Inc yet.
Sana Biotechnology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes…
Full company profileSana Biotechnology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sana Biotechnology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.00K | -3.92M | -10.2M | -17.9M | -27.7M | -30.9M | -15.5M | -12.8M | - |
| Operating Income | -8.22M | -141M | -286M | -357M | -273M | -293M | -273M | -191M | -113M |
| EBITDA | -13.2M | -141M | -280M | -346M | -257M | -259M | -251M | -231M | -104M |
| Net Income | -13.2M | -131M | -279M | -344M | -266M | -283M | -267M | -244M | -121M |
| EPS | -0.07 | -0.70 | -1.49 | -2.07 | -1.41 | -1.46 | -1.16 | -0.96 | -0.39 |
| Balance Sheet | |||||||||
| Total Assets | 34.3M | 415M | 730M | 1.13B | 823M | 565M | 501M | 417M | 376M |
| Total Liabilities | 47.5M | 558M | 1.15B | 401M | 323M | 278M | 251M | 256M | 196M |
| Shareholders' Equity | -13.2M | -143M | -421M | 729M | 499M | 288M | 251M | 161M | 180M |
| Cash & Short-term Investments | 30.6M | 139M | 378M | 551M | 424M | 205M | 152M | 138M | 122M |
| Total Debt | - | 47.7M | 71.9M | 111M | 108M | 104M | 94.2M | 78.9M | 53.8M |
| Cash Flow | |||||||||
| Operating Cash Flow | -13.5M | -85.5M | -138M | -251M | -290M | -254M | -223M | -144M | -145M |
| Capital Expenditure | 460K | 26.2M | 23.9M | 29.9M | 20.9M | 20.0M | 33.4M | 938K | 3.60M |
| Free Cash Flow | -14.0M | -112M | -162M | -281M | -311M | -274M | -257M | -145M | -149M |
| Ratios | |||||||||
| ROE | - | - | - | -47.2% | -53.4% | -98.5% | -106.5% | -151.8% | -66.9% |
| ROA | -38.6% | -31.5% | -38.2% | -30.5% | -32.4% | -50.1% | -53.2% | -58.6% | -32.1% |
| Debt to Equity | - | - | - | 0.15x | 0.22x | 0.36x | 0.38x | 0.49x | 0.30x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sana Biotechnology Inc dividends
Sana Biotechnology Inc has not paid dividends in the last 8 fiscal years.
Who owns Sana Biotechnology Inc
- Insiders 6.08%
- Institutions 76.88%
- Public & others 17.05%
- Shares outstanding 300M
- Free float 191M
Top funds holding SANA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 10.5M | 3.50% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6.25M | 2.09% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 5.86M | 1.96% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 4.35M | 1.45% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 3.12M | 1.04% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 2.86M | 0.95% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 2.01M | 0.67% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.62M | 0.54% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 1.44M | 0.48% | -0.19% | Oct 2026 |
| Fidelity Select Biotechnology | 1.26M | 0.42% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 1.00M | 0.33% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 996K | 0.33% | -5.60% | Sep 2026 |
| Fidelity Extended Market Index | 909K | 0.30% | +6.56% | Sep 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 664K | 0.22% | -0.83% | Sep 2026 |
| iShares U.S. Small-Cap Eq Fac ETF | 606K | 0.20% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 529K | 0.18% | +0.11% | Sep 2026 |
| DWS ESG Biotech LC | 446K | 0.15% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 417K | 0.14% | -6.76% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 382K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 328K | 0.11% | -0.05% | Sep 2026 |
Top institutions holding SANA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 37.4M | 12.49% | 0.00% | Jun 2026 |
| Flagship Ventures Management, Inc. | 25.0M | 8.34% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 18.8M | 6.26% | 0.00% | Jun 2026 |
| BlackRock Inc | 16.7M | 5.57% | +17.10% | Jun 2026 |
| State Street Corp | 11.2M | 3.74% | +6.31% | Jun 2026 |
| Canada Pension Plan Investment Board | 10.2M | 3.41% | -0.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 8.38M | 2.80% | +12.65% | Jun 2026 |
| Bank of America Corp | 5.75M | 1.92% | +95.07% | Jun 2026 |
| Geode Capital Management, LLC | 4.68M | 1.56% | +11.86% | Jun 2026 |
| Marex Group Ltd | 3.99M | 1.33% | -0.25% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.93M | 0.98% | +341.18% | Jun 2026 |
| Alphabet Inc | 2.81M | 0.94% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.37M | 0.79% | -25.56% | Jun 2026 |
| Integral Health Asset Management, LLC | 2.00M | 0.67% | -37.50% | Jun 2026 |
| The Toronto-Dominion Bank | 1.97M | 0.66% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.88M | 0.63% | +10.20% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.87M | 0.62% | 0.00% | Jun 2026 |
| Northern Trust Corp | 1.60M | 0.54% | +8.47% | Jun 2026 |
| Renaissance Technologies Corp | 1.42M | 0.47% | +15.47% | Sep 2026 |
| Charles Schwab Investment Management Inc | 1.38M | 0.46% | +0.95% | Jun 2026 |
Sana Biotechnology Inc company profile
- Company name
- Sana Biotechnology Inc
- Ticker
- SANA.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Fiscal year end
- December
- Address
- 188 East Blaine Street, Seattle, WA, United States, 98102
- Phone
- 206 701 7914
- Website
- sana.com
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Sana Biotechnology Inc management
10- Dr. Steven D. Harr M.D.President, CEO & Director · born 1970
- Mr. Brian D. Piper M.B.A.Executive VP & CFO · born 1972
- Ms. Susan WyrickTreasurer, Principal Accounting Officer and Senior VP of Finance & Accounting · born 1973
- Mr. Snehal PatelExecutive VP & Chief Technical Officer
- Dr. Dhavalkumar D. Patel M.D., Ph.D.Executive VP & Chief Scientific Officer · born 1961
- Mr. Aaron M. GrossmanExecutive VP, Chief Legal Officer & Corporate Secretary · born 1972
- Ms. Debra WisdomVP & Head of People
- Dr. Gary Meininger M.D.Executive VP & Chief Medical Officer
- Dr. Yuko Soneoka J.D., Ph.D.SVP & Head of Intellectual Property
- Mr. John Gerecitano M.D., Ph.D.Senior Vice President, Clinical Lead, Hematology & Oncology Development